ArticleMicrobial biotechnology2026
Applying Baculovirus Surface Display Technology for Influenza Cytokine Profiling, Serological Detection and Antiviral Screening.
Article in Microbial biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Influenza causes approximately one billion infections and hundreds of thousands of deaths each year. Occasionally, highly pathogenic new virus strains emerge. Research on emerging influenza viruses or multiple viral strains is often limited by the need for high biosafety level (BSL) laboratories. To overcome this limitation, we attempt to establish a BSL-1-compatible influenza research platform using baculovirus surface display technology. We constructed influenza virus pseudotypes HA-Bac and NA-Bac by displaying hemagglutinin (HA) and neuraminidase (NA) proteins from influenza viruses on the surface of baculoviruses. Different HA-Bac and NA-Bac induced a unique inflammatory cytokine profile after transduction into respiratory epithelial and macrophage cell lines. Using insect cells infected with these HA-Bac and NA-Bac as antigens, we established cell-based and lysate-based ELISA to detect HA and NA antibodies. The lysate-based ELISA showed excellent performance in detecting IgG antibodies in patients' serum samples. Finally, hemagglutination induced by HA-Bac-infected insect cells and neuraminidase activity generated by NA-Bac-infected cells were both inhibited by the corresponding antiviral drugs in functional inhibition assays. In summary, this study established a safe influenza research system capable of performing cytokine profiling, serological detection and antiviral drug screening under BSL-1 conditions. This system holds promise for application to other emerging respiratory viruses and support of public health preparedness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.